Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ITOS 
Iteos Therapeutics Inc (ITOS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/29/2025: ITOS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $10.35
1 Year Target Price $10.35
| 3 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -15.37% | Avg. Invested days 32 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/29/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 448.68M USD | Price to earnings Ratio - | 1Y Target Price 10.35 |
Price to earnings Ratio - | 1Y Target Price 10.35 | ||
Volume (30-day avg) 6 | Beta 1.49 | 52 Weeks Range 4.80 - 12.30 | Updated Date 09/15/2025 |
52 Weeks Range 4.80 - 12.30 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.73 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -18.49% | Return on Equity (TTM) -34.97% |
Valuation
Trailing PE - | Forward PE 12.56 | Enterprise Value -61617211 | Price to Sales(TTM) 12.78 |
Enterprise Value -61617211 | Price to Sales(TTM) 12.78 | ||
Enterprise Value to Revenue 1.26 | Enterprise Value to EBITDA 0.5 | Shares Outstanding 44205400 | Shares Floating 33493988 |
Shares Outstanding 44205400 | Shares Floating 33493988 | ||
Percent Insiders 0.35 | Percent Institutions 90.28 |
Upturn AI SWOT
Iteos Therapeutics Inc
Company Overview
History and Background
Iteos Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing next-generation cancer immunotherapies. Founded in 2011 and headquartered in Cambridge, MA, Iteos focuses on modulating the tumor microenvironment to enhance anti-tumor immunity.
Core Business Areas
- Drug Discovery and Development: Focuses on the discovery and development of novel cancer immunotherapies.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
- Research and Development: Engages in ongoing research to identify new targets and develop innovative therapies.
Leadership and Structure
The leadership team includes Michel Detheux (CEO), Dr. Melissa Roman (CMO), and Jean-Francois Veyron (COO). The organizational structure comprises research, development, clinical operations, and commercial strategy teams.
Top Products and Market Share
Key Offerings
- EOS-448 (anti-TIGIT antibody): An anti-TIGIT antibody currently in clinical development for various cancers. It targets the TIGIT receptor on immune cells. Market share is still developing as it's in clinical trials. Competitors include Roche (TIGIT program).
- EOS-850 (A2AR antagonist): An A2AR antagonist designed to block adenosine signaling in the tumor microenvironment. It's in clinical trials for solid tumors. Market share is still developing as it's in clinical trials. Competitors include Arcus Biosciences (AB928).
Market Dynamics
Industry Overview
The oncology market is highly competitive, with a growing focus on immunotherapies. There's a strong demand for innovative cancer treatments that improve patient outcomes.
Positioning
Iteos Therapeutics positions itself as an innovator in immuno-oncology, focusing on modulating the tumor microenvironment. Its competitive advantage lies in its novel targets and combination therapy approach.
Total Addressable Market (TAM)
The global oncology market is projected to reach billions of dollars. Iteos Therapeutics is positioned to capture a portion of this market by developing novel immunotherapies, focused mainly on indications that have high unmet needs. TAM is difficult to quantify due to stage of drug pipeline, but the overall Immuno-oncology TAM is estimated to be over $150 Billion by 2030.
Upturn SWOT Analysis
Strengths
- Novel therapeutic targets
- Strong research and development pipeline
- Experienced management team
- Strategic partnerships
Weaknesses
- Limited commercialized products
- Dependence on clinical trial outcomes
- High research and development costs
- Susceptibility to regulatory hurdles
Opportunities
- Expansion of clinical trials
- Potential for FDA approval of drug candidates
- Strategic collaborations and acquisitions
- Development of combination therapies
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Changes in regulatory landscape
- Patent disputes
Competitors and Market Share
Key Competitors
- Roche (RHHBY)
- Arcus Biosciences (RCUS)
- Bristol-Myers Squibb (BMY)
Competitive Landscape
Iteos Therapeutics faces competition from established pharmaceutical companies with broader portfolios. Its advantage lies in its novel targets and focused approach.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by the progression of drug candidates through clinical trials and strategic partnerships.
Future Projections: Future growth is dependent on the successful completion of clinical trials and potential FDA approval of its drug candidates. Analyst estimates vary based on clinical data and market potential.
Recent Initiatives: Recent initiatives include expanding clinical trials for EOS-448 and EOS-850, and pursuing strategic collaborations with other pharmaceutical companies.
Summary
Iteos Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel cancer immunotherapies. Its strengths lie in its innovative research and promising drug candidates. However, it faces risks associated with clinical trial outcomes and competition from larger players. Positive clinical data and strategic partnerships are crucial for future success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Iteos Therapeutics Investor Relations
- SEC Filings
- Analyst Reports
- Company Press Releases
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Iteos Therapeutics Inc
Exchange NASDAQ | Headquaters Watertown, MA, United States | ||
IPO Launch date 2020-07-24 | President, CEO & Director Dr. Michel Detheux Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 173 | |
Full time employees 173 | |||
iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of T-cell immunoreceptor with Ig and ITIM domains (TIGIT), as well as engages the Fc gamma receptor to activate dendritic cells, natural killer cells, T lymphocytes, and macrophages and to promote the release of cytotoxic granules and antibody-dependent cellular cytotoxicity activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonist program; EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to reverse immunosuppression and restore T cell proliferation in the tumor microenvironment; and EOS-215, a monoclonal antibody which antagonizes triggering receptor expressed on triggering receptor expressed on myeloid cells 2. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts. As of August 28, 2025, iTeos Therapeutics, Inc. operates as a subsidiary of Concentra Biosciences, LLC.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.